Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

Ugur Sahin, the co-founder and CEO of BioNTech SE (BNTX), sold $119.58 million worth of the Germany-based biotechnology company’s stock last week. This is the first big Informative Sell ...

Ugur Sahin, CEO of BioNTech. The company earned more than €20 billion from the sales of the COVID-19 vaccine developed with ...

Reports Q4 revenue EUR 1.19B vs. EUR 1.48B last year. “From the very beginning, BioNTech’s (BNTX) vision has been to translate our science into ...

She has a Neutral rating and price target of $110. BioNTech’s founders, Ugur Sahin, the CEO, and his wife, Ozlem Tureci, the ...

The design work has been done by the Netherlands’ Ugur Sahin Design, while the carbon fiber fabrication is to be handled by ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

We look forward to providing more updates this year across our oncology portfolio, including our bispecific antibody and ADC programs,” said Ugur Sahin, CEO and Co-Founder of BioNTech.

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...